PUS1 May Be a Potential Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma
DOI: https://doi.org/10.2147/PGPM.S405621
2023-04-16
Pharmacogenomics and Personalized Medicine
Abstract:Chenlu Lan, 1, 2, &ast Xinlei Huang, 1, 2, &ast Xiwen Liao, 1, 2 Xin Zhou, 1, 2 Kai Peng, 1, 2 Yongguang Wei, 1, 2 Chuangye Han, 1, 2 Tao Peng, 1, 2 Jianyao Wang, 3 Guangzhi Zhu 1, 2 1 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China; 2 Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, 530021, People's Republic of China; 3 Department of General Surgery, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guangzhi Zhu, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China, Tel +86-771-5356528, Fax +86-771-5350031, Email Jianyao Wang, Department of General Surgery, Shenzhen Children's Hospital, Lianhua District, Shenzhen, 518026, Guangdong Province, People's Republic of China, Email Objective: The mechanisms of pseudouridine synthase (PUS) are not definite in hepatocellular carcinoma (HCC), the objective of this study is to investigate the effect of PUS genes in HCC. Materials and Methods: Differentially expressed and prognostic gene of PUS enzymes was identified based on The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and Gene Expression Profiling Interactive Analysis (GEPIA) databases. For the identified gene, pseudouridine synthase 1 ( PUS1 ), was used for further research. The clinicopathological feature of PUS1 was analyzed by Student's t -test. Prognostic significance was explored by Kaplan-Meier (KM) analysis and Cox proportional hazards regression model. Receiver operating characteristic (ROC) curve was applied to appraise diagnostic and prognostic value. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) and Gene Set Enrichment Analysis (GSEA) were implemented to explore mechanism of PUS1 . A Guangxi cohort was applied to verify differential expression. In vitro cell experiments were implemented to investigate the influence for proliferation, reactive oxygen species (ROS) level, migration, and invasion of HCC cells after a knockdown of PUS1 . Results: PUS1 was significantly overexpressed in HCC tissues, and patients with high PUS1 were related to unpromising clinicopathological features. Survival analysis revealed high PUS1 expression was associated with a poor overall survival (OS) and 1 year-recurrence free survival (RFS), was an independent risk factor. Meanwhile, ROC curve showed that PUS1 had a diagnostic and prognostic significance to HCC. Functional enrichment analysis implied that PUS1 may be involved in metabolic pathways, mitochondrial function, non-alcoholic fatty liver disease (NAFLD), and some important carcinogenic pathways. Cell assays revealed that knockdown of PUS1 significantly constrained the migration, proliferation, invasion and improved the ROS level of HCC cells. Conclusion: PUS1 may be a prognostic biomarker and a underlying treatment target for HCC. Keywords: PUS1 , pseudouridine synthase, poor prognosis, gene knockout, HCC Cancer brings a heavy burden to society, primary liver cancer has the seventh incidence and second mortality rates worldwide, about 75–85% of patients of primary liver cancer are HCC. 1 Primary prevention contributes to reduce the incidence of HCC. Early diagnosis and management can improve OS for HCC patients. 2 Currently, early detection of HCC still depends on ultrasonography and serum α-fetoprotein (AFP), yet the accuracy for early stage is not so satisfactory. 3 Therefore, substantial studies focus on seeking new biomarkers or tests which have a better diagnostic or prognostic value for HCC. Protein Induced by Vitamin K Absence or antagonist-II (PIVKA-II) 4 and AFP isoform L3 (AFP-L3) 5 have been applied for early detection and postoperative surveillance for HCC. The GALAD scoring system, consists of gender, age, AFP-L3, AFP and PIVKA-II, is a preferable approach for HCC detection. 6 In addition, many valuable biomarkers have emerged, 7 but the efficiency needs to be further determined clinically. Identification of novel biomarkers for diagnosis and surveillance -Abstract Truncated-
pharmacology & pharmacy